---
title: "Daiichi Sankyo’s Enhertu plus pertuzumab wins EU CHMP backing for first-line HER2+ metastatic breast cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293745706.md"
description: "The EU's CHMP has recommended approving Daiichi Sankyo’s Enhertu combined with pertuzumab for first-line HER2-positive metastatic breast cancer. This recommendation, based on DESTINY-Breast09 data showing a 44% reduction in progression or death risk, clears the path for European Commission review. If approved, it will be the first new first-line option in over a decade."
datetime: "2026-07-24T11:01:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293745706.md)
  - [en](https://longbridge.com/en/news/293745706.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293745706.md)
generator: "portal-rs"
---

# Daiichi Sankyo’s Enhertu plus pertuzumab wins EU CHMP backing for first-line HER2+ metastatic breast cancer

-   EU drug regulator’s CHMP backed Enhertu with pertuzumab for first-line HER2-positive metastatic breast cancer, clearing the file for European Commission review. \* Recommendation followed DESTINY-Breast09 data showing a 44% lower risk of progression or death versus THP; median PFS 40.7 months versus 26.9 months. \* If cleared, the regimen would be the first new EU first-line option in more than a decade for this setting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607240700BIZWIRE\_USPR\_\_\_\_\_20260723\_BW402930) on July 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [DSNKY.US](https://longbridge.com/en/quote/DSNKY.US.md)
- [4568.JP](https://longbridge.com/en/quote/4568.JP.md)

## Related News & Research

- [Daiichi promotes Ken Keller to lead new commercialization unit](https://longbridge.com/en/news/296867871.md)
- [JAZZ: FDA approved Ziihera regimens for first-line HER2+ GEA, setting a new standard of care](https://longbridge.com/en/news/296933637.md)
- [BeOne says FDA approves Tevimbra-based first-line regimen for HER2+ gastroesophageal cancer](https://longbridge.com/en/news/296930925.md)
- [ExpreS2ion says ES2B-C001 Phase I trial shows anti-HER2 antibody response in 12 of 13 patients, no dose-limiting toxicities](https://longbridge.com/en/news/296452642.md)
- [Thomson Reuters built its own AI model off Chinese tech to rely less on Claude](https://longbridge.com/en/news/296792919.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**